Allergies News and Research

Latest Allergies News and Research

Researchers to begin drug development projects for rare and neglected diseases

Researchers will begin drug development projects for rare and neglected diseases that include potential treatments for a musculoskeletal disorder, a cognitive dysfunction disorder, a virus that affects the central nervous system of newborns, a parasitic worm infection, a form of muscular dystrophy and a rare lung disease.

16 Nov 2011

CDC launches new antibiotic tracking system

The Centers for Disease Control and Prevention is launching a new antibiotic tracking system allowing hospitals to monitor antibiotic use electronically, make better decisions about how to improve use, and compare themselves to other hospitals. Before now, CDC was only able to track antibiotic use in doctors' offices.

15 Nov 2011

Possible link between norovirus and food allergies

Researchers at the Medical College of Wisconsin have found a possible link between norovirus, a virus that causes "stomach flu" in humans, and food allergies.

15 Nov 2011

Ampion safe and effective for patients with nasal inflammation

Ampio Pharmaceuticals, Inc., a company that discovers and develops new uses for previously approved drugs and new molecular entities, today announced that an IRB approved, randomized, vehicle-controlled, double-blinded study conducted at Centers for Allergy and Asthma in Denver, Colorado indicates that Ampion provides safe and effective anti-inflammatory relief when administered intranasally to patients with nasal inflammation.

11 Nov 2011

Long-range wind transport of an infectious agent may cause KD

Kawasaki Disease (KD) is a severe childhood disease that many parents, even some doctors, mistake for an inconsequential viral infection. In fact, if not diagnosed or treated in time, it can lead to irreversible heart damage. After 50 years of research, including genetic studies, scientists have been unable to pinpoint the cause of the disease.

10 Nov 2011

Mylan acquires rights to Pfizer's inhalation technology platform

Mylan Inc. today announced that it has entered into an agreement with Pfizer for the exclusive worldwide rights to develop, manufacture and commercialize Pfizer's generic equivalent to GlaxoSmithKline's Advair Diskus and Seretide Diskus incorporating Pfizer's proprietary dry powder inhaler delivery platform.

10 Nov 2011

HyQ phase III study data in patients with primary immunodeficiencies presented at ACAAI meeting

Baxter International Inc. today announced the presentation of its phase III study data for HyQ, an investigational combination immunoglobulin (IG) product for use in patients with primary immunodeficiencies (PI).

From Baxter International Inc. 7 Nov 2011

Respiratory problems in homes on the rise due to air freshners

Sales of home air fresheners and scented candles are on the rise and so are respiratory problems in homes where these products are used, according to allergists at the annual scientific meeting of the American College of Allergy, Asthma and Immunology (ACAAI) in Boston, Nov 3-8.

7 Nov 2011

Experts share latest buzz on allergies to alcohol and tobacco

While the health benefits of drinking wine in moderation continue to make news, for some with allergies even a glass a day may be difficult to swallow. At the annual scientific meeting of the American College of Allergy, Asthma and Immunology (ACAAI) in Boston, Nov. 3-8, allergists share the latest buzz on allergies to alcohol and tobacco.

7 Nov 2011

New long-term data from Abbott's HUMIRA plus methotrexate Phase 3 studies on RA

Abbott today announced results from long-term open-label extensions of the PREMIER and DE019 Phase 3 studies, which evaluated HUMIRA (adalimumab) plus methotrexate (MTX) for up to eight years in patients with early moderate to severe rheumatoid arthritis (RA) and up to 10 years in patients with long-standing moderate to severe RA, respectively.

7 Nov 2011

Tips to reduce animal dander in home

Good news for the millions of dog and cat lovers whose four-legged friend is causing them to sneeze and wheeze.—removing the pet from the home isn't the only option. At the annual scientific meeting of the American College of Allergy, Asthma and Immunology (ACAAI) in Boston, Nov. 3-8, allergists discuss the use of immunotherapy - allergy shots - combined with environmental changes to help control pet allergy symptoms.

7 Nov 2011

Rheumavax safe and feasible in treating RA

A vaccine designed to re-educate the immune system has been shown to be safe and feasible in the treatment of rheumatoid arthritis, according to research presented this week at the American College of Rheumatology Annual Scientific Meeting in Chicago.

7 Nov 2011

Single-parent status, household income linked to increased rate of hospital readmissions of asthmatic children

Financial strain and competing priorities at home may contribute to the greater number of hospital readmissions of children with asthma from single-parent homes compared to dual-parent households, according to a new study presented at the American College of Allergy, Asthma and Immunology Annual Meeting in Boston, Nov. 3-8.

5 Nov 2011

Sunovion reports positive results from ciclesonide nasal aerosol Phase III study for perennial allergic rhinitis

Sunovion Pharmaceuticals Inc. today announced results from a large Phase III clinical study of ciclesonide nasal aerosol, a corticosteroid formulated with a hydrofluoroalkane (HFA) propellant, intended for the treatment of allergic rhinitis.

5 Nov 2011

States lack policies to curb classroom burden of asthma and severe allergies

For over 7 million children with asthma, and 13 million with food allergy or other severe allergies, going to school is a daily risk affecting how well they can – or can't – manage their diseases. Now for the fourth year, the Asthma and Allergy Foundation of America has released its annual report assessing all 50 states and the District of Columbia on their leadership and progress on school-based policies that address student asthma and allergy health in more than 100,000 elementary, middle and high schools across the U.S.

5 Nov 2011

Reduced diversity of intestinal microbiota associated with increased risk of allergic disease

Oversensitivity diseases, or allergies, now affect 25 per cent of the population of Denmark. The figure has been on the increase in recent decades and now researchers at the Copenhagen Prospective Studies on Asthma in Childhood (COPSAC), University of Copenhagen, are at last able to partly explain the reasons.

3 Nov 2011

EBV vaccine could prevent mononucleosis and cancers linked to virus

In a new article from the National Institutes of Health (NIH), Anthony S. Fauci, M.D., director of the National Institute of Allergy and Infectious Diseases (NIAID), and Harold Varmus, M.D., director of the National Cancer Institute (NCI), join Gary Nabel, M.D., Ph.D., director of NIAID's Vaccine Research Center, and Jeffrey Cohen, M.D., chief of NIAID's Laboratory of Infectious Diseases, in summarizing a recent meeting of experts who gathered to map directions toward an EBV vaccine.

3 Nov 2011

Allergy shots are cost-effective and deliver relief in weeks

Allergy shots, an age-old treatment for allergy sufferers, are getting a shot in the arm from new research. This proven therapy saves money; accelerated schedules deliver relief in weeks, rather than months; and alternative methods are on the horizon, according to allergists at the annual scientific meeting of the American College of Allergy, Asthma and Immunology in Boston, Nov 3-8.

3 Nov 2011

State roundup: Ga., Minn. move slowly on exchanges

The entire Massachusetts congressional delegation is asking CMS to preserve the level of safety net funding and provider payments as the state tries to renew its Medicaid waiver. "We are concerned that changes proposed by CMS could significantly threaten payments to Massachusetts health care providers providing care for the most vulnerable populations," Sens. John Kerry and Scott Brown and the 10 House members in the state's delegation wrote.

2 Nov 2011

Perrigo's partner receives final approval for Epinastine HCl ophthalmic solution

Perrigo Company today announced that its partner, PharmaForce/Luitpold Pharmaceuticals, received final approval for Epinastine HCl ophthalmic solution, 0.05%, a generic version of Elestat. Perrigo will commence shipment of the product immediately.

2 Nov 2011